Lush Prize 2026, a fund supporting animal testing alternatives, awards Harvard Ph.D. for groundbreaking 'Cervix-Vagina Chip' for women's disease research.

'Cervix-Vagina Chip' image

On Tuesday, May 12, 2026, the British natural cosmetics brand LUSH and the UK consumer organization Ethical Consumer Research Association announced the winners of the 'Lush Prize 2026,' the world's largest fund promoting the research and development of animal testing alternatives and activities to abolish animal testing.

This year's Science Prize was awarded to Dr. Zohreh Izadifar of Harvard University, who developed the world's first 'Cervix-Vagina Chip,' which reproduces female reproductive functions on a microchip. These chips are already being used to advance the understanding of vaginal health, preterm birth, and infertility.

What is the Lush Prize?

Established in 2012 to support R&D that does not rely on animal testing and to promote activities aimed at abolishing animal testing. It is the largest in the field of promoting animal testing alternatives and is unique in its focus solely on 1R (Replacement)*1. To date, it has awarded over £3 million (approx. 585 million JPY*2) in prize money. This year, a total of £250,000 (approx. 48.75 million JPY) is being awarded to activists and researchers around the world in five categories, including the Science Prize.

5 Award Categories

Public Awareness: For individuals and groups who have contributed to informing society about the background and reality of animal testing.

Science: For researchers and research institutions engaged in the R&D of non-animal alternative methods.

Training: For individuals, groups, or organizations that provide training in non-animal alternative methods for researchers and regulators.

Political Advocacy: For individuals and groups that conduct policy interventions aimed at replacing and banning animal testing, targeting regulatory bodies and governments. *Formerly the 'Lobbying' category.

Young Researcher: For researchers aged 35 or under (at the time of application) who are developing and researching non-animal alternative methods.

The full list of winners will be available on the Lush Prize official website from Wednesday, May 13.

About the Lush Prize 2026 Science Prize Winner

On Tuesday, May 12, 2026, Dr. Zohreh Izadifar of Harvard University accepted the 'Science Prize' on stage at the award ceremony in London. Dr. Izadifar's team developed the 'Cervix-Vagina Chip,' a microchip about the size of a USB drive. Equipped with electrical sensors, this chip can analyze in real-time how human vaginal and cervical cells respond to hormones, beneficial bacteria, and infections.

This technology is revolutionary because it can precisely replicate 'human-specific physiological phenomena' that were difficult to study with animal testing. A major factor in the slow progress of women's disease research has been the physiological differences between humans and animals commonly used in research, such as mice. For example, mice do not menstruate or go through menopause, nor do they share the common hormonal and microbial characteristics seen in humans. This chip overcomes the limitations of animal testing by using human cells to create a highly simulated in-body environment. It is already being used to deepen the understanding of vaginal health, preterm birth, and infertility, and is expected to aid in elucidating many long-neglected women's diseases and developing safer, more effective treatments.

The Lush Prize judges are particularly pleased to have been able to award this prize for such a groundbreaking achievement in the important and under-researched field of 'women's health.'

Comment from Dr. Izadifar:

'Winning the Lush Prize is a recognition of our efforts to advance the future of biomedical research without animal testing. This award highlights the urgent need to develop preclinical models that faithfully replicate female biology and to deliver better, more effective treatments for long-neglected diseases. Animal testing not only has ethical concerns but also scientific limitations. Many treatments that showed promise in animal models fail to be effective in humans, resulting in significant financial losses and delays in patient care. By replacing animal models with advanced human-derived systems, we can fundamentally improve our understanding of disease, accelerate drug discovery, and develop safer, more effective treatments.'

<Contact>

LUSH (Lush Japan)

0120-125-204

support@lush.co.jp

https://www.lush.co